Here’s Why Abbott Laboratories (ABT) Traded Down in Q3

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the market's performance. A significant portion of the market is currently tied to the single catalyst of AI deployment, which means that any weaknesses in this concept could significantly threaten the market's future strength. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a leading manufacturer of health care products. The one-month return of Abbott Laboratories (NYSE:ABT) was -1.89%, and its shares lost 9.73% of their value over the last 52 weeks. On November 11, 2025, Abbott Laboratories (NYSE:ABT) stock closed at $127.00 per share, with a market capitalization of $220.837 billion.

Carillon Eagle Growth & Income Fund stated the following regarding Abbott Laboratories (NYSE:ABT) in its third quarter 2025 investor letter:

"Abbott Laboratories (NYSE:ABT) underperformed in the third quarter, largely due to disappointing second-quarter financial results and a downward revision of its financial guidance. While most business segments are performing well, the company’s diagnostics segment is facing challenges in China, driven by soft economic conditions and government pressure on medical product pricing."Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Abbott Laboratories (NYSE:ABT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 69 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the second quarter, compared to 70 in the previous quarter.  While we acknowledge the potential of Abbott Laboratories (NYSE:ABT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the list of best dividend aristocrat stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

Story Continues

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments